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Abstract
Over the past 20 years, substantial progress has been made in identifying the underlying genetics of Parkinson’s
disease (PD). Of the known genes, LRRK2 is a major genetic contributor to PD. However, the exact function of
LRRK2 remains to be elucidated. In this review, we discuss how familial forms of PD have led us to hypothesize that
alterations in endomembrane trafficking play a role in the pathobiology of PD. We will discuss the major observations
that have been made to elucidate the role of LRRK2 in particular, including LRRK2 animal models and high-throughput
proteomics approaches. Taken together, these studies strongly support a role of LRRK2 in vesicular dynamics. We also
propose that targeting these pathways may not only be beneficial for developing therapeutics for LRRK2-driven PD,
but also for other familial and sporadic cases.
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Background
Understanding the etiology of a disease is often an im-
portant step for developing treatments. With many of
the common neurodegenerative diseases, it is clear
that single gene mutations account for some propor-
tion of all cases while the rest are ‘sporadic’ in nature.
This leads to the concept that genetic variants, acting
within the context of the aging central nervous system
and stochastic factors, leads to overall risk of disease.
Thus, the etiology of neurodegeneration is at least
partially tractable.
Parkinson’s disease (PD) falls within this rubric, in that
about 10% of cases have a clear family history while the
remainder are scattered throughout the population. The
nature of inheritance is variable, with both dominant
and recessive genes being found that have age-dependent
penetrance. Furthermore, within the sporadic PD popu-
lation, genome-wide association studies (GWAS) have
nominated multiple genomic regions as harboring vari-
ants that contribute to overall risk of disease throughout
lifetime. PD genetics is therefore rarely pure and never
simple but contributes to pathogenesis and, by exten-
sion, might be leveraged for therapeutic benefit.
Here, we will focus on one specific gene for PD that is
relevant for both inherited and sporadic disease that has
been the subject of recent attention as a potential drug
target. We will focus specifically on the underlying biol-
ogy that has been uncovered in recent years to discuss
the concept of pathway risk in parkinsonism.
LRRK2 is in a pleomorphic risk locus for PD
In 2002, inherited PD in a large Japanese kindred was
linked to the PARK8 locus on chromosome 12 [1]. The
same locus was found in independently ascertained
families from different countries [2–4] and the under-
lying genetic cause, a mutation in the LRRK2 gene, was
discovered 2 years later [3, 5] an a series of LRRK2
mutations nominated in additional families [6–10]. To
date, five mutations in LRRK2 have been shown unam-
biguously to segregate with familial PD and two additional
variants have been nominated as risk factors (reviewed
in [11, 12]). All of these LRRK2 mutations show age-
dependent incomplete penetrance, meaning that some
LRRK2 mutation carriers do not show clinical pheno-
types during their lifetime [13].
Independently of mutations, GWAS approaches have
also identified LRRK2 to be a risk factor for sporadic PD
[14]. The precise mechanism by which variations around
the LRRK2 gene region contribute to disease risk are not
fully resolved, but given that the polymorphisms
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associated with sporadic PD are in the promoter region
of LRRK2, a reasonable hypothesis is that these variants
do not change protein structure or function but instead
alter expression levels of the gene, although this remains
to be formally demonstrated for LRRK2. The chromo-
somal region containing LRRK2 is therefore an example
of a pleomorphic risk locus, i.e. a genomic region that
harbors variants that increase disease risk but by differ-
ent mechanisms [15]. Additionally, LRRK2-driven PD is
clinically indistinguishable from idiopathic PD [16]. Col-
lectively, these observations suggest that LRRK2 plays a
general role in the etiological mechanisms of both inher-
ited and sporadic PD.
LRRK2 structure and enzymatic domains
LRRK2 encodes a large (2527 amino acid) multi-domain
protein termed leucine rich repeat kinase 2 (LRRK2).
The central portion of LRRK2 contains a Ras of Com-
plex (Roc) GTPase and a C-terminus of Roc (COR) do-
main, followed immediately by a kinase domain. The
ROC-COR bidomain and kinase region together consti-
tute the catalytic core of LRRK2, which therefore en-
compasses two enzymatic activities. Several protein
interaction domains surround this catalytic core, includ-
ing N-terminal armadillo (Arm), ankyrin (Ank) and leu-
cine rich repeat (LRR) domains and a C-terminal WD40
domain (Fig. 1). Interestingly, all the segregating muta-
tions associated with PD are located within the enzym-
atic core of LRRK2 (Fig. 1) and mutated proteins have
altered biochemical activity in vitro [17]. There are sub-
tle differences between mutations, as the kinase domain
mutations including G2019S and I2020T directly
increase kinase activity [13] whereas those in the ROC-
COR domains, the best studied of which are R1441C/G
and Y1699C, decrease GTPase activity [18–21]. How-
ever, it is thought that the physical proximity of two
enzyme activities encoded in the same protein structure
implies that they regulate each other and lead to a co-
ordinated output in cellular signaling [22, 23]. Therefore,
even if mutations have differing effects on the proximal
biochemical activity of LRRK2, they are likely to have a
consistent effect on signaling in the cell. By extension, it
is likely that evolution has selected for the multiple en-
zymatic and protein interaction domains of LRRK2 to be
on a single polypeptide because they work together to
generate one or more cellular outputs.
Despite being a large protein, several early studies
showed that LRRK2 can form homodimers that localize
to membrane compartments of the cell [24–26]. It is
likely that dimer formation is part of the complex auto-
regulatory function of LRRK2, relevant for the kinase
and GTPase activities discussed above. Recently, a 3D
structural model of full length LRRK2 has been described,
showing that the LRRK2 homodimer adopts a compact
architecture, highly suggestive of intramolecular regula-
tion of the enzymatic activities [27]. In this model, the
protein-protein interaction domains either serve to
stabilize the dimer internally or are surface available for
interactions with external binding partners (Fig. 1).
These biochemical and structural observations suggest,
first, that LRRK2 is a co-ordinated signaling molecule
that has linked enzyme activities and potentially multiple
protein interaction partners and, second, that mutations
associated with PD can modify these activities.
Fig. 1 Overview of LRRK2 domain organization. a Linear model of the LRRK2 domains and pathogenic mutations. b Schematic model of
homodimeric, folded LRRK2 and the approximate positioning of domains within the 3D LRRK2 structure
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Genetic clues for altered vesicular dynamics in PD
The next important question, is what effects LRRK2 has
within cells and, therefore, within the organism. If we
make the assumption that LRRK2 has some higher-level
relationship with other genetic forms of PD, we might
ascertain some candidates for LRRK2’s cellular role.
The first gene cloned for inherited PD was SNCA,
which encodes a small vesicular protein abundantly
expressed in the brain, α − synuclein. As for LRRK2, the
genetic region surrounding SNCA is a pleomorphic risk
locus, containing point mutations, gene multiplications
and risk variants for sporadic PD. Furthermore, aggrega-
tion of insoluble α-synuclein is one of the main patho-
logical hallmarks of PD, in the form of Lewy bodies and
Lewy neurites in multiple brain regions. Because of this
accumulation of protein, impaired degradation pathways
have been hypothesized to be one of the underlying
disease mechanisms of PD [28]. Because neurons re-
quire substantial maintenance and recycling of vesicles
and their associated proteins at synapses, a particularly
attractive idea is that PD might result from a failure of
degradative pathways for vesicular proteins. The majority
of α-synuclein is degraded through the lysosome, per-
haps by a specialized process called chaperone-mediated
autophagy (CMA) [29]. It is known that CMA activity
diminishes with age [30] and that the protein stability of
α-synuclein increases with age as well as mutations [31].
With the assumption that multiplication mutations in
SNCA increase protein levels, a possible explanation for
the age-dependent penetrance of these mutations is that
the protein levels are a critical driver of toxic events in
the brain.
Since the initial cloning of SNCA, there have been
multiple PD-related genes identified that additionally
converge on the related autophagy-lysosome system and
vesicle trafficking pathways (summarized in Table 1,
extensively reviewed in [28, 32]). We will therefore
summarize some of the key characteristics and players
in these intracellular events before turning to the
evidence that addresses the role(s) of LRRK2 in vesicle
uptake and recycling.
The endosomal and autophagosomal pathways
Two major pathways for cellular homeostasis are endo-
cytosis and autophagy (2). During endocytosis, extracel-
lular components are engulfed at the plasma membrane
and transported and sorted via early and late endosomes
[33]. The eventual destinations of endocytosed materials
are varied, including rapid recycling at the post-synaptic
region of neurons [34]. However, a subset of endosomes
matures for subsequent fusion events with other intra-
cellular membranous vesicles. This is a highly regulated
process influenced by several cellular signaling pathways,
with key involvement of the members of the Rab family
of membrane-associated small GTPases [35]. Early endo-
somes are enriched in the signaling lipid PI(3)P, gener-
ated by the VPS34 complex. Conversion of PI(3)P to
PI(3,5)P2 by the kinase PIKFyve is important for endo-
some maturation [36], where Rab5-positive early endo-
somes mature to Rab7-positive late endosomes through
a transient Rab5/Rab7-postive structure [37]. Rab9 and
Rab7L1 are involved in the recycling of endosomal
vesicles to the trans Golgi network (TGN) via several
protein complexes called the retromer [38]. Outside of
endosomes, other Rabs are critical for different mem-
brane trafficking and fusion events. Rab8 and Rab10
mediate the transport of vesicles from the TGN to the
plasma membrane, whereas Rab32 and Rab38 are
Table 1 PD-associated genes with a role in endomembrane trafficking. AD autosomal dominant, AR autosomal recessive
Gene Inheritance Role in endomembrane trafficking References
Parkin AR Ubiquitination of damaged mitochondria for degradation by mitophagy [86, 87]
PINK1 AR Phosphorylation of mitochondria for parkin activation and mitophagy [87–89]
DJ-1 AR Mitophagy, mitochondrial dynamics [87, 90, 91]
Fbxo7 AR Mitophagy, interacts with parkin [92]
α-synuclein AD/risk factor Substrate of CMA, pathogenic α-synuclein inhibits CMA and induces macroautophagy [14, 28, 29, 93]
LRRK2 AD/risk factor Autophagy, endomembrane trafficking [14, 28]
Vps35 AD Component of the retromer complex [94, 95]
ATP13A2 AR Lysosomal P5-type ATPase [96]
DNAJC6 AR Co-chaperone in clathrin-mediated trafficking [97, 98]
SYNJ1 AR Lipid phosphatase in clathrin mediated trafficking [99]
GAK Risk factor Co-chaperone in clathrin-mediated trafficking, LRRK2 interactor [14, 73]
Rab7L1 Risk factor Small GTPase regulating endomembrane trafficking, LRRK2 interactor [14, 73]
GBA Risk factor Lysosomal protease [14, 100]
TMEM230 AD Transmembrane protein of recycling/secretory vesicles [101]
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involved in the transport of specialized endomembrane
compartments called melanosomes to the plasma
membrane [39] (Fig. 2). Thus, the endosomal pathway
consists of a series of discrete membrane organelles
that rely on Rabs and other signaling molecules for effi-
cient regulation.
Autophagy is derived from Greek root words for ‘self-
eating’. This highly regulated process maintains cellular
homeostasis through lysosomal degradation of cellular
components. There are three major types of autophagy:
chaperone-mediated autophagy (CMA), microautophagy
and macroautophagy. During CMA, substrates are
selectively but directly delivered to the lysosomes by
Hsc-70 and a specific lysosomal membrane receptor,
LAMP2A [30]. In microautophagy, cellular targets are
directly translocated to the lysosomes but in a relatively
nonselective manner that involves invagination and
scission of the lysosomal membrane [40].
Macroautophagy, often referred to as simply ‘autophagy’
due to it being relatively better studied than the other
two processes, involves sequestration of substrates into
a specialized organelle, the autophagosome [41]. The
underlying process can be broken down into 3 steps:
phagophore formation, elongation of the phagophore to
encircle the cargo and finally fusion of the autophago-
some with lysosomes, membrane bound organelles that
are enriched for proteolytic enzymes to enable degrad-
ation of their cargo (Fig. 2).
Like the endosomal system, autophagy is highly regulated
by several cellular signaling pathways. In the canonical
pathway, activation of the Ulk1 complex through mTOR
signaling is necessary for autophagy autophagy induction.
Next, the vacuolar sorting protein 34 (VPS34) complex is
relocated to the phagophore for the generation of phos-
phatidylinositol 3 phosphate (PI(3)P). The local enrichment
of PI(3)P recruits proteins associated with the initiation of
autophagy, including WIPI2 [42]. Non-canonical, PI3K-
independent induction of autophagy has recently been re-
ported as well [43]. WIPI2 next functions to recruit and
conjugate Atg (autophagic genes) proteins to mediate the
elongation of the phagophore. In this step, the cytosolic
LC3-I is cleaved and lipidated to form LC3-II on the autop-
hagosomal membrane. This conversion of LC3-I to LC3-II
is necessary for phagophore elongation to form an enclosed
vesicle and is widely used as a marker for the presence of
active autophagy in cells and tissues. Finally, the autopha-
gosome fuses with lysosomes forming autolysosomes [42].
There are also specialized forms of autophagy for
degradation of selective cargoes. Several organelles can
be degraded after fusion with autophagosomes, for
example depolarized mitochondria are cleared by mito-
phagy [44, 45]. In most of these cases, there are adaptor
proteins that bridge the cargo to the developing au-
tophagic membrane [46], including the general adaptor
p62/sequestosome that is also often used to identify the
presence of autophagy in tissues [47].
Fig. 2 Cartoon of endosomal trafficking and macroautophagy. WIPI2 is involved in the initiation of autophagy at the phagophore. LC3-II is involved
for the elongation of the autophagosomal membrane. Phagosomes are formed upon the phagocytosis of extracellular pathogens. Rab proteins,
including Rab5, Rab7, Rab9, Rab7L1, Rab8, Rab10, Rab12, Rab32 and Rab38 are key regulators of endomembrane trafficking. Autophagosomes and
endosomes can fuse to form amphisomes. Amphisomes on their turn fuse with lysosomes for degradation of the autophagic/endocytic cargo. Grey
shade indicates the involvement of LRRK2 in endomembrane trafficking through physical interactors and/or kinase substrates. Pink shade highlights
parts of endomembrane trafficking where LRRK2 is implied having a regulatory role
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Although the above discussion outlines endosomal
and autophagy as discrete pathways, in practice there is
extensive cross talk between these vesicular events. For
example, a subset of endosomes will fuse either directly
with lysosomes in a Rab12-dependent manner or indir-
ectly after first fusing with autophagosomes, to generate
multivesicular bodies (MVBs) or amphisomes. Even
more impressively, while lysosomes might be described
as a waste disposal, in fact they are an important signal-
ing platform, for example by controlling transcriptional
responses to cellular metabolic state [48]. Therefore,
there are likely to be signaling events that co-ordinate
the overall balance between degradation and recycling
of membranes and proteins in the cell.
A physiological role for LRRK2 at vesicular
membranes
The first indications for a role of LRRK2 in vesicular
dynamics came from subcellular localization studies,
showing localization of LRRK2 with endosomes, lyso-
somes and MVBs in rodent brain [49] and with punc-
tate, vesicular structures in human brain [49, 50].
Studies in cells overexpressing low levels of tagged
LRRK2 showed specific localization of LRRK2 to MVBs
and autophagic vacuoles [51]. Collectively, these obser-
vations suggest that LRRK2 may have a regulatory role
in the autophagic and endosomal pathways.
LRRK2 KO models: clues for a physiological role of LRRK2
in autophagy and lysosomal function
Important evidence for a physiological role of LRRK2
in regulating autophagy came from knockout animals.
Specifically, there is an accumulation of lipofuscin
granules, aggregated α-synuclein and increased levels of
the autophagosomal marker LC3-II in LRRK2 knockout
kidneys [52]. These effects are age-dependent, in that
there are bi-phasic alterations in autophagy, with an
initial increase of p62 and LC3-II at 7 months and a
decrease at 20 months. No changes in LC3-II were
observed in an independent study of kidneys of
14 month-old LRRK2 KO mice [53].
However, no apparent signs of neurodegeneration have
been observed in LRRK2 KO rodents. The 6-fold higher
expression levels of LRRK2 in kidney compared to brain
and the absence of its homologue LRRK1 may explain
this severe kidney phenotype [52, 54]. Knockout of
dLrrk, the single Drosophila homologue of LRRK1/2,
has been shown to cause alterations in lysosomal posi-
tioning [55]. Along the same lines, knockout of the
single C elegans homologue, Lrk-1 m causes defects in
synaptic vesicle protein positioning in neurons [56].
Several studies in cells have indicated a role for LRRK2
in the regulation of autophagy. Under conditions that
stimulate autophagy but prevent fusion to lysosomes,
knockdown of LRRK2 led to a decreased accumulation of
autophagosomes [57]. LRRK2 kinase inhibition has also
been shown to increase levels of the lipdated autophago-
some marker LC3-II and the adaptor protein p62 [58, 59].
Recent findings have shown that this kinase-dependent
regulation of LC3 lipidation is mediated through Beclin-1
signaling but independent of mTOR/ULK1 signaling, sug-
gesting non-canonincal regulation of autophagy [60].
There is a potential discrepancy between LC3-II levels,
which generally increase with LRRK2 knockout or kinase
inhibition [58, 59], and accumulation of autophago-
somes, which decrease under similar conditions [57]. Iit
is important to note that at steady state these two mea-
sures can be difficult to interpret in terms of overall flux
through the autophagy pathway. For example, both in-
duction of autophagy and inhibition of autophagosome
clearance results in the accumulation of lipidated LC3-
II. In H-4 cells, a combined treatment with a LRRK2
kinase inhibitor and bafilomycin, to block lysosomal
acidification, results in an additive increase in LC3-II
[58]. This suggests that LRRK2 inhibition does not block
flux through the overall autophagy pathway but rather
increases formation of autophagosomes. By extension,
these considerations suggest that LRRK2 normally func-
tions to block autophagosome formation.
However, even these data are complicated by the ob-
servation that, in microglial cells, knockdown of LRRK2
can decrease LC3-II formation after lysosomal inhibition
[57], in contrast to increases in mice [52] and H4 cells
[58, 59]. It is possible therefore that there are cell-
type specific signaling events that can modulate the
direction of effect of LRRK2 on autophagy markers,
indicating that autophagy regulation may be a down-
stream consequence of LRRK2 deficiency rather than
a primary event.
In addition, higher levels of lysosomal markers and the
lysosomal protease cathepsin D are seen in LRRK2
knockout mouse kidneys compared to their wild type
counterparts irrespective of age [54]. Similar phenotypic
changes, including lipofuscin accumulation and increase
in lysosomal markers have been observed in LRRK2 KO
rats [61, 62]. Therefore, while influencing autophago-
some formation, LRRK2 may also play a role in lyso-
somal maturation and/or trafficking. How these two
events are related is not immediately clear and, given
then age-dependence of some changes [52, 54], it
remains possible that alterations in one part of the
autophagy-lysosome system are compensated for by
alterations in other degradative processes.
Pathogenic mutations in LRRK2 KO affect vesicular events
in vitro and in vivo
The above data show that the normal function of LRRK2
appears to be related to vesicular trafficking. Several
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observations in different systems further suggest that
LRRK2 mutations across multiple domains of the pro-
tein also alter vesicular dynamics.
Fibroblasts derived from PD patients carrying muta-
tions across several enzymatic domains of LRRK2
(G2019S, Y1669C, R1441C) show a diminished autoph-
agic response to starvation, measured by LC-3 conver-
sion, compared to control fibroblasts [63]. Cells
overexpressing R1441C LRRK2 show an increase in
MVBs and autophagic vacuoles [51]. Overexpression of
G2019S in cells also results in an increase in autophagic
vacuoles and decreased neuronal process length.
Knockdown of the conserved autophagy genes LC3 and
Atg7 as well as inhibition of ERK signaling reversed this
effect [64]. Overexpression of wild type LRRK2 in cells
has also been reported to result in an increase of autop-
hagosomes [65].
iPSC derived dopaminergic neurons from G2019S
mutation carriers show an increase of autophagic vacu-
oles and an accumulation of aggregated α-synuclein
[66, 67]. In these cells, there were no changes in SNCA
transcription, suggesting an impaired degradation of α-
synuclein [67]. G2019S LRRK2 iPSC showed a decrease
in neurite length compared to control iPSC and induc-
tion of autophagy further exacerbated this phenotype
[66]. An independent study of G2019S iPSC derived
dopaminergic neurons and isogenic controls also
showed neurite shortening in an ERK-dependent way
[67]. Notably, G2019S LRRK2-mediated effects on au-
tophagy in cells have also been reported to be mediated
through ERK signaling [68]. Finally, in vivo, mice carry-
ing the G2019S mutation show an accumulation of au-
tophagic vacuoles in the cerebral cortex, as do R1441C
LRRK2 transgenic mice [69].
The collective data available therefore suggests that
mutant forms of LRRK2 decrease LC3 lipidation and
result in the accumulation of autophagic vacuoules.
The observations with LC3 are consistent with the data
from knockout and inhibition models that LRRK2
normal function is to block autophagosome formation
and that dominant mutations enhance this activity.
However, the subsequent accumulation of autophagic
vesicles suggests that there are additional effects of
mutations in LRRK2 on the overall function of the
autophagy-lysosomal pathway. One possible explan-
ation for this apparent discrepancy comes from the
observec concurrent increase in autophagic vacuoles
and accumulation of α-synuclein in cells with G2019S
LRRK2 [66, 67]. Because α-synuclein is degraded by the
lysosome [70], the available data could suggest that
G2019S mutant of LRRK2 simultaneously block autop-
hagosome formation and lysosomal function, which
contrasts perhaps with the accumulation of lysosomal
enzymes in LRRK2 knockout animals [52, 54].
Candidate mechanisms for LRRK2 effects on vesicular
trafficking
There are several potential mechanisms by which
LRRK2 may affect vesicular trafficking. Indirect mech-
anism, such as those where LRRK2 has direct effects on
metabolic or cellular signaling pathways that then indir-
ectly affect autophagy, may explain some of the ob-
served correlated changes noted above. However, here
we will focus on regulation of vesicular trafficking
events that are potentially mediated by direct protein-
protein interactions. The rationale for this limitation on
discussion of mechanisms is that as LRRK2 has mul-
tiple protein interaction domains, these are likely im-
portant effectors of its function in cells.
Unbiased proteomics approaches have provided im-
portant insights into the functional roles of LRRK2.
Rab5 was first found to interact with LRRK2 using a
yeast-two-hybrid screening approach [71]. Conversely,
LRRK2 was identified as an interaction partner in a
yeast-two-hybrid screen for Rab32 [72]. High-
throughput protein-protein interaction arrays have
shown that LRRK2 physically interacts with Rab7L1
(also known as Rab29) [73]. In the latter case, we
have found that Rab7L1/Rab29 is important for
recruiting LRRK2 to the TGN, along with the
clathrin-uncoating protein cyclin-G associated kinase
(GAK) and the co-chaperone BAG5. This protein
complex may be conserved as similar proteins are
important for the recruitment of Lrk-1 to the golgi
apparatus in C elegans [74], Importantly, Rab7L1 and
GAK are nominated to be risk factors for sporadic
PD [14]. Clearance of Golgi-derived vesicles by the
LRRK2 complex including Rab7L1 is enhanced by
mutations across all enzymatic domains of LRRK2
whereas hypothesis testing LRRK2 mutations, includ-
ing those that are kinase dead or cannot bind GDP/
GTP, were ineffective in TGN vesicle clearance [73].
This suggests that enzymatic activities of LRRK2 are
required to promote TGN clustering and clearance
and that pathogenic mutations result in a gain-of-
function that enhance this phenotype [73].
In addition, LRRK2 was shown to interact with a
number of other Rab GTPases, including Rab32 and
Rab38 [72]. Recently, phosphoproteomic screens were
performed in an effort to identify bona fide LRRK2 kin-
ase substrates [75]. Two screens were performed using
cells from mice engineered to have either the kinase
hyperactive G2019S or kinase inhibitor resistant
A2016T LRRK2, in combination with treatment of dis-
tinct LRRK2 kinase inhibitors. Overlap of these screens
resulted in the identification of a single LRRK2 kinase
substrate, Rab10. Further analysis in HEK293FT cells
indicated that Rab10 as well as Rab8 and Rab12 are dir-
ect physiological LRRK2 substrates [75].
Roosen and Cookson Molecular Neurodegeneration  (2016) 11:73 Page 6 of 10
Although publication of independent confirmation of
these findings is still awaited, they suggest that one of
the key functions of LRRK2, kinase activity, is important
in control of Rabs and, hence vesicular trafficking
events. Furthermore, in cells (but not in vitro), muta-
tions in several different regions of LRRK2 consistently
result in increased Rab phosphorylation, supporting the
contention that different LRRK2 domains work together
to produce functional output [75]. Along the same lines,
all pathogenic mutations in LRRK2 increase Rab7L1-
dependent retention at the TGN [73]. However, the pre-
cise mechanism(s) by which LRRK2 domains interact in
cells remain to be determined.
Collectively, these data place LRRK2 at the scene of
the crime for vesicle sorting. A recent computational
analysis of the LRRK2 interactome further supports a
potential role for LRRK2 in vesicular dynamics such as
endocytosis and autophagy [76]. However, the range of
Rabs identified suggests multiple roles for LRRK2 at
different intracellular membranes. It is also of interest
that LRRK2 has a different set of Rabs that appear to
be direct substrates from those that were nominated as
stronger binding partners, perhaps suggesting that de-
pending on the Rab, LRRK2 may have different modes
of action. Further confirmation of the binding and
phosphorylation events are needed before we can be
certain of the precise role that LRRK2 plays in Rab biol-
ogy and vice-versa. Nonetheless, because Rab proteins
are important in vesicular dynamics, these results sug-
gest that the mechanism by which LRRK2 affects intra-
cellular membranes is mediated via Rab interactions.
There are several pieces of evidence to suggest that, in
different tissues and systems, the physiological inter-
action with Rabs is important for mediating the effects
of mutations in LRRK2 on membrane trafficking. As
well as causing changes in autophagy, pathogenic LRRK2
mutations have also been shown to lead to alterations in
synaptic vesicle trafficking in neurons. Rab5 has a par-
ticularly strong role in synaptic vesicle endocytosis.
Overexpression of WT LRRK2 impaired synaptic vesicle
endocytosis and this effect was further enhanced by
overexpression of G2019S LRRK2, whereas-expression
of Rab5 rescued this phenotype [77].
Further supporting the idea that LRRK2 and Rabs co-
operate to modulate vesicular trafficking, Rab7L1 KO
mice have the same lysosomal pathology in the kidneys
as LRRK2 KO mice and the combined deficiency of both
proteins also results in a similar phenotype suggesting a
genetic interaction with consistent direction between
these two proteins [78]. Whether this is true for other
Rabs that are direct substrates of LRRK2 is not known,
and future studies are required to further substantiate
the relationship between LRRK2, Rabs and regulation of
the autophagy-lysosome system.
Studies in C. elegans neurons suggest that suggests
that the LRRK2 nematode ortholog acts downstream of
Rab7L1 ortholog in endo-lysosomal trafficking. Further-
more, cellular work showed that LRRK2 interacts with
AP-3 as a downstream effector, essential for trafficking
of lysosomal membrane proteins from the Golgi to the
lysosomes [78]. The Drosophila homolog of LRRK2
(dLrrk) colocalizes with endosomes and lysosomes and
interacts late endosomal protein Rab7. dLrrk loss-of-
function mutants have abnormalities in the endosome
and dLrrk can negatively regulate Rab7-dependent peri-
nuclear localization of lysosome [55]. In contrast, a
mutation in dLrrk corresponding to the G2019S muta-
tion in LRRK2 promotes Rab7-dependent perinuclear
positioning of lysosomes [55]. Accumulation of autop-
hagosomes and presence of enlarged lysosomes and
endosomes were also observed in dLrrk loss-of-
function mutants [79]. This phenotype was rescued by
overexpression of Rab9, which promotes recycling of
endosomes to the TGN via the retromer, again possibly
due to a direct interaction [79]. As noted above, dLrrk
is paralog of LRRK1/LRRK2 [80] and therefore may
interact with a slightly different or broader set of Rabs
than LRRK2. Nonetheless, these collective data strongly
suggest that the effects of LRRK2 across several species
depend on Rab GTPases in different tissues and cells,
not just in neurons.
Fibroblasts of PD patients carrying the G2019S muta-
tion showed decreased Rab7 activity. Overexpression of
G2019S as well as R1441C LRRK2 cause a decrease of
Rab7 activity in cells [81]. Moreover, expression of mu-
tant LRRK2 caused a delay in early to late endosomal
trafficking, as evidenced by a decreased Rab5 to Rab7
transitioning [81]. A dramatic delay of trafficking out of
late endosomes was observed in cells overexpressing
G2019S and R1441C LRRK2. These late endosomes
showed a marked increase in Rab7-positive tubules [81].
However, in addition to Rab proteins, LRRK2 may also
mechanistically alter membrane dynamics via other im-
portant interacting proteins. LRRK2 has been shown to
interact and colocalize with Sec16, a key protein in-
volved in ER-Golgi transport [82]. The R1441C LRRK2
mutation impaired this interaction and mouse primary
fibroblasts from R1441C transgenic mice showed im-
paired ER to Golgi trafficking [82].
LRRK2 and its Drosophila homologue dLRRK were
shown to phosphorylate the synaptic vesicle endocytosis
protein endophilin-A in vitro [83, 84]. In Drosophila, in-
creased endophilinA phosphorylation by G2019S dLrrk
resulted impaired synaptic endocytosis [83]. Moreover,
dLRRK-dependent phosphorylation of endophilinA was
recently shown to stimulate autophagy in at Drosophila
synapses, highlighting cross-talk between endosomal and
autophagosomal signaling networks [85].
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Collectively, these data show that LRRK2 can interact
with multiple vesicle-associated proteins. One of the
most important remaining questions for LRRK2 biology
is how binding to Rabs or other proteins influences the
observed alterations in autophagy and lysosomal markers
seen in cells and animal models, or whether other mech-
anisms are at play. A particular complexity of vesicular
trafficking is that events are often inter-related as, for
example, multiple Rabs co-operate to influence overall
protein and vesicle sorting [35]. Thus, overall flux through
a pathway may depend on interactions between multiple
partners some of which may anatogonize each other. Fur-
ther complicating interpretation, presumably most tissues
and cells have compensatory mechanisms that will at least
partially recover function in vesicle sorting. It will there-
fore be important to examine multiple steps of vesicular
sorting to see which are consistently and directly affected
by LRRK2 deficiency and mutations to determine which
events are direct and which are consequential.
Conclusions
A substantial amount of evidence shows that LRRK2
plays an important role in vesicular trafficking. LRRK2
KO models and studies using LRRK2 kinase inhibitors
have highlighted a regulatory role for LRRK2 in au-
tophagy. Proteomics approaches have greatly helped to
identify physical interactors as well as bona fide kinase
substrates of LRRK2. Importantly, given the high inter-
connectivity of endosomal, lysosomal and autophago-
somal pathways, dysfunctions in one system may well
trigger alterations in another.
However, how altered vesicular trafficking can ultimately
lead to neurodegeneration is not well understood in the
context of LRRK2 mutations. Understanding such patho-
biological roles of LRRK2 is critical for the development
of therapeutic strategies. If LRRK2 mutations result in a
gain of biochemical function, targeting the kinase and/or
GTPase activity of LRRK2 could be helpful to modulate
disease progression. More broadly, if it is true that mul-
tiple PD-related genes converge on vesicular trafficking
pathways, regulatory and partially redundant mechanisms
for autophagy might be targetable for therapeutics.
Abbreviations
AD: Autosomal dominant; Ank: Ankyrin; AR: Autosomal recessive;
Arm: Armadillo, Atg, Autophagic genes; CMA: Chaperone-mediated
autophagy; COR: C-terminus of Roc; LRR: Leucine rich repeat; LRRK1/
2: Leucine rich repeat kinase 1/2; MVB: Multivesicular body; PD:
Parkinson’s disease; PI(3)P: Phosphatidylinositol 3-phosphate;
PI(3,5)P2: Phosphatidylinositol 3,5-biphosphate; Roc: Ras of complex;




This research was supported by the Intramural Research Program of the NIH,
National Institute on Aging.
Availability of data and materials
Not applicable.
Authors’ contributions
DR and MRC wrote the manuscript. Both authors read and approved the
final manuscript.
Competing interests
The authors declare that they have no competing interests.
Consent for publication
Not applicable.
Ethics approval and consent to participate
Not applicable.
Author details
1Cell Biology and Gene Expression Section, Laboratory of Neurogenetics,
National Institute on Aging, National Institutes of Health, Bldg. 35, 35
Convent Drive, Bethesda, MD 20892-3707, USA. 2School of Pharmacy,
University of Reading, Whiteknights, Reading RG6 6AP, UK.
Received: 26 October 2016 Accepted: 3 December 2016
References
1. Funayama M, Hasegawa K, Kowa H, Saito M, Tsuji S, Obata F. A new locus
for Parkinson’s disease (PARK8) maps to chromosome 12p11.2-q13.1. Ann
Neurol. 2002;51:296–301.
2. Zimprich A, Müller-Myhsok B, Farrer M, Leitner P, Sharma M, Hulihan M, et
al. The PARK8 locus in autosomal dominant parkinsonism: confirmation of
linkage and further delineation of the disease-containing interval. Am J
Hum Genet. 2004;74:11–9.
3. Khan NL, Jain S, Lynch JM, Pavese N, Abou-Sleiman P, Holton JL, et al.
Mutations in the gene LRRK2 encoding dardarin (PARK8) cause familial
Parkinson’s disease: clinical, pathological, olfactory and functional imaging
and genetic data. Brain. 2005;128:2786–96.
4. Wszolek ZK, Pfeiffer RF, Tsuboi Y, Uitti RJ, McComb RD, Stoessl AJ, et al.
Autosomal dominant parkinsonism associated with variable synuclein
and tau pathology. Neurology. 2004;62:1619–22.
5. Zimprich A, Biskup S, Leitner P, Lichtner P, Farrer M, Lincoln S, et al.
Mutations in LRRK2 cause autosomal-dominant parkinsonism with
pleomorphic pathology. Neuron. 2004;44:601–7.
6. Mata IF, Kachergus JM, Taylor JP, Lincoln S, Aasly J, Lynch T, et al. Lrrk2
pathogenic substitutions in Parkinson’s disease. Neurogenetics. 2005;6:171–7.
7. Zabetian CP, Samii A, Mosley AD, Roberts JW, Leis BC, Yearout D, et al. A
clinic-based study of the LRRK2 gene in Parkinson disease yields new
mutations. Neurology. 2005;65:741–4.
8. Di Fonzo A, Rohe C, Ferreira J, Chien H, Vacca L, Stocchi F, et al. A frequent
gene mutation associated with autosomal dominant Parkinson’s disease.
Lancet. 2005;365:412–5.
9. Gilks WP, Abou-Sleiman PM, Gandhi S, Jain S, Singleton A, Lees AJ, et al.
A common LRRK2 mutation in idiopathic Parkinson’s disease. Lancet.
2005;365:415–6.
10. Funayama M, Hasegawa K, Ohta E, Kawashima N, Komiyama M, Kowa H, et
al. An LRRK2 mutation as a cause for the parkinsonism in the original PARK8
family. Ann Neurol. 2005;57:918–21.
11. Paisán-Ruiz C, Lewis PA, Singleton AB. LRRK2: cause, risk, and mechanism.
J Park Dis. 2013;3:85–103.
12. Dächsel JC, Farrer MJ. LRRK2 and Parkinson disease. Arch Neurol. 2010;67:542–7.
13. Cookson MR. LRRK2 pathways leading to neurodegeneration. Curr Neurol
Neurosci Rep. 2015;15:564.
14. Nalls MA, Pankratz N, Lill CM, Do CB, Hernandez DG, Saad M, et al. Large-scale
meta-analysis of genome-wide association data identifies six new risk loci for
Parkinson’s disease. Nat Genet (Nature Publishing Group). 2014;46:989–93.
15. Singleton A, Hardy J. A generalizable hypothesis for the genetic architecture
of disease: pleomorphic risk loci. Hum Mol Genet. 2011;20:R158–62.
16. Hardy J, Cai H, Cookson MR, Gwinn-Hardy K, Singleton A. Genetics of
Parkinson’s disease and parkinsonism. Ann Neurol. 2006;60:389–98.
Roosen and Cookson Molecular Neurodegeneration  (2016) 11:73 Page 8 of 10
17. Rudenko IN, Cookson MR. Heterogeneity of leucine-rich repeat kinase 2
mutations: genetics, mechanisms and therapeutic implications.
Neurotherapeutics. 2014;11:738–50.
18. Lewis PA, Greggio E, Beilina A, Jain S, Baker A, Cookson MR. The R1441C
mutation of LRRK2 disrupts GTP hydrolysis. Biochem Biophys Res Commun.
2007;357:668–71.
19. Daniẽls V, Vancraenenbroeck R, Law BMH, Greggio E, Lobbestael E, Gao F, et
al. Insight into the mode of action of the LRRK2 Y1699C pathogenic
mutant. J Neurochem. 2011;116:304–15.
20. Liao J, Wu C-X, Burlak C, Zhang S, Sahm H, Wang M, et al. Parkinson
disease-associated mutation R1441H in LRRK2 prolongs the “active state”
of its GTPase domain. Proc Natl Acad Sci U S A. 2014;111:4055–60.
21. Guo L, Gandhi PN, Wang W, Petersen RB, Wilson-Delfosse AL, Chen SG.
The Parkinson’s disease-associated protein, leucine-rich repeat kinase 2
(LRRK2), is an authentic GTPase that stimulates kinase activity. Exp Cell Res.
2007;313:3658–70.
22. Rosenbusch KE, Kortholt A. Activation mechanism of LRRK2 and its cellular
functions in Parkinson’s disease. Park Dis. 2016;2016:7351985.
23. Mata IF, Wedemeyer WJ, Farrer MJ, Taylor JP, Gallo KA. LRRK2 in
Parkinson’s disease: protein domains and functional insights. Trends
Neurosci. 2006;29:286–93.
24. Gloeckner CJ, Kinkl N, Schumacher A, Braun RJ, O’Neill E, Meitinger T, et al.
The Parkinson disease causing LRRK2 mutation I2020T is associated with
increased kinase activity. Hum Mol Genet. 2006;15:223–32.
25. Greggio E, Zambrano I, Kaganovich A, Beilina A, Taymans JM, Daniels V, et
al. The Parkinson disease-associated leucine-rich repeat kinase 2 (LRRK2) is a
dimer that undergoes intramolecular autophosphorylation. J Biol Chem.
2008;283:16906–14.
26. Zdenek B, Smith KA, Lavoie MJ. Membrane localization of LRRK2 is
associated with increased formation of the highly active LRRK2 dimer and
changes in its phosphorylation. Biochemistry (Mosc). 2010;49:5511–23.
27. Guaitoli G, Raimondi F, Gilsbach BK, Gómez-Llorente Y, Deyaert E, Renzi F, et
al. Structural model of the dimeric Parkinson’s protein LRRK2 reveals a
compact architecture involving distant interdomain contacts. Proc Natl
Acad Sci (National Academy of Sciences). 2016;113:E4357–66.
28. Beilina A, Cookson MR. Genes associated with Parkinson’s disease: regulation
of autophagy and beyond. J. Neurochem. 2015;n/a – n/a.
29. Cuervo AM, Stefanis L, Fredenburg R, Lansbury PT, Sulzer D. Impaired
Degradation of Mutant α -Synuclein by Chaperone-Mediated Autophagy.
Science. 2004;305(5688):1292–5.
30. Cuervo AM, Wong E. Chaperone-mediated autophagy: roles in disease and
aging. Cell Res (Nature Publishing Group). 2014;24:92–104.
31. Li W. Stabilization of -synuclein protein with aging and familial Parkinson’s
disease-linked A53T mutation. J Neurosci. 2004;24:7400–9.
32. Kumaran R, Cookson MR. Pathways to parkinsonism redux: convergent
pathobiological mechanisms in genetics of Parkinson’s disease. Hum Mol
Genet. 2015;9:1–37.
33. Jovic M, Sharma M, Rahajeng J, Caplan S. The early endosome: a busy sorting
station for proteins at the crossroads. Histol Histopathol. 2010;25:99–112.
34. Sudhof TC. The synaptic vesicle cycle. Annu Rev Neurosci. 2004;27:509–47.
35. Stenmark H. Rab GTPases as coordinators of vesicle traffic. Nat Rev Mol Cell
Biol. 2009;10:513–25.
36. Marat AL, Haucke V. Phosphatidylinositol 3 -phosphates — at the interface
between cell signalling and membrane traffic. EMBO J. 2016;35:561–79.
37. Vanlandingham PA, Ceresa BP. Rab7 Regulates Late Endocytic Trafficking
Downstream of Multivesicular Body Biogenesis and Cargo Sequestration *. J
Biol Chem. 2009;284:12110–24.
38. Huotari J, Helenius A. Endosome maturation. EMBO J (Nature Publishing Group).
2011;30:3481–500.
39. Zhen Y, Stenmark H. Cellular functions of Rab GTPases at a glance. J Cell Sci.
2015;128:3171–6.
40. Wen-wen L, Jian L, Jin-ku B. Microautophagy: lesser-known self-eating. J Cell
Mol Life Sci. 2012;69:1125–36.
41. Feng Y, He D, Yao Z, Klionsky DJ. The machinery of macroautophagy. Cell Res.
2014;24:24–41.
42. Behrends C, Sowa ME, Gygi SP, Harper JW. Network organization of the
human autophagy system. Nature (Nature Publishing Group). 2010;466:68–76.
43. Vicinanza M, Korolchuk V, Ashkenzai A, Puri C, Menzies F, Clarke J, et al.
PI(5)P regulates autophagosome biogenesis. Mol Cell Biol. 2015;57.
44. Okamoto K. Organellophagy: eliminating cellular building blocks via
selective autophagy. J Cell Biol. 2014;205:435–45.
45. Youle RJ, Narendra DP. Mechanisms of mitophagy. Nat Rev Mol Cell Biol.
2011;12:9–14.
46. Xu Z, Yang L, Xu S, Zhang Z, Cao Y. The receptor proteins: pivotal roles in
selective autophagy. Acta Biochim Biophys Sin. 2015;47:571–80.
47. Bitto A, Lerner CA, Nacarelli T, Crowe E, Torres C, Sell C. P62/SQSTM1 at the
interface of aging, autophagy, and disease. Age Dordr Neth. 2014;36:9626.
48. Lim C-Y, Zoncu R. The lysosome as a command-and-control center for
cellular metabolism. J Cell Biol. 2016;214:653–64.
49. Biskup S, Moore DJ, Celsi F, Higashi S, West AB, Andrabi SA, et al.
Localization of LRRK2 to membranous and vesicular structures in
mammalian brain. Ann Neurol. 2006;60:557–69.
50. Higashi S, Biskup S, West AB, Trinkaus D, Dawson VL, Faull RLM, et al.
Localization of Parkinson’s disease-associated LRRK2 in normal and
pathological human brain. Brain Res. 2007;1155:208–19.
51. Alegre-Abarrategui J, Christian H, Lufino MMP, Mutihac R, Venda LL,
Ansorge O, et al. LRRK2 regulates autophagic activity and localizes to
specific membrane microdomains in a novel human genomic reporter
cellular model. Hum Mol Genet. 2009;18:4022–34.
52. Tong Y, Yamaguchi H, Giaime E, Boyle S, Kopan R, Kelleher RJ, et al. Loss of
leucine-rich repeat kinase 2 causes impairment of protein degradation
pathways, accumulation of alpha-synuclein, and apoptotic cell death in
aged mice. Proc Natl Acad Sci U S A. 2010;107:9879–84.
53. Herzig MC, Kolly C, Persohn E, Theil D, Schweizer T, Hafner T, et al. LRRK2
protein levels are determined by kinase function and are crucial for kidney
and lung homeostasis in mice. Hum Mol Genet. 2011;20:4209–23.
54. Tong Y, Giaime E, Yamaguchi H, Ichimura T, Liu Y, Si H, et al. Loss of
leucine-rich repeat kinase 2 causes age-dependent bi-phasic alterations
of the autophagy pathway. Mol Neurodegener. 2012;7:2.
55. Dodson MW, Zhang T, Jiang C, Chen S, Guo M. Roles of the Drosophila
LRRK2 homolog in Rab7-dependent lysosomal positioning. Hum Mol Genet.
2012;21:1350–63.
56. Sakaguchi-Nakashima A, Meir JY, Jin Y, Matsumoto K, Hisamoto N. LRK-1, a
C. elegans PARK8-related kinase, regulates axonal-dendritic polarity of SV
proteins. Curr Biol. 2007;17:592–8.
57. Schapansky J, Nardozzi JD, Felizia F, LaVoie MJ. Membrane recruitment of
endogenous LRRK2 precedes its potent regulation of autophagy. Hum Mol
Genet. 2014;23:4201–14.
58. Manzoni C, Mamais A, Dihanich S, Abeti R, Soutar MPM, Plun-Favreau H, et
al. Inhibition of LRRK2 kinase activity stimulates macroautophagy. Biochim
Biophys Acta (The Authors). 1833;2013:2900–10.
59. Saez-Atienzar S, Bonet-Ponce L, Blesa JR, Romero FJ, Murphy MP, Jordan J,
et al. The LRRK2 inhibitor GSK2578215A induces protective autophagy in
SH-SY5Y cells: involvement of Drp-1-mediated mitochondrial fission and
mitochondrial-derived ROS signaling. Cell Death Dis. 2014;5:e1368.
60. Manzoni C, Mamais A, Roosen DA, Dihanich S, Soutar MPM, Plun-Favreau H,
et al. mTOR independent regulation of macroautophagy by Leucine Rich
Repeat Kinase 2 via Beclin-1. Sci Rep. 2016;6:35106.
61. Baptista MAS, Dave KD, Frasier MA, Sherer TB, Greeley M, Beck MJ, et al. Loss
of leucine-rich repeat kinase 2 (LRRK2) in rats leads to progressive abnormal
phenotypes in peripheral organs. PLoS One. 2013;8:e80705.
62. Ness D, Ren Z, Gardai S, Sharpnack D, Johnson VJ, Brennan RJ, et al. Leucine-rich
repeat kinase 2 (LRRK2)-deficient rats exhibit renal tubule injury and perturbations
in metabolic and immunological homeostasis. PLoS One. 2013;8:e66164.
63. Manzoni C, Mamais A, Dihanich S, McGoldrick P, Devine MJ, Zerle J, et al.
Pathogenic Parkinson’s disease mutations across the functional domains of
LRRK2 alter the autophagic/lysosomal response to starvation. Biochem
Biophys Res Commun (Elsevier Inc). 2013;441:862–6.
64. Plowey ED, Cherra SJ, Liu YJ, Chu CT. Role of autophagy in G2019S-LRRK2-
associated neurite shortening in differentiated SH-SY5Y cells. J Neurochem.
2008;105:1048–56.
65. Gómez-Suaga P, Luzón-Toro B, Churamani D, Zhang L, Bloor-Young D, Patel S,
et al. Leucine-rich repeat kinase 2 regulates autophagy through a calcium-
dependent pathway involving NAADP. Hum Mol Genet. 2012;21:511–25.
66. Sánchez-Danés A, Richaud-Patin Y, Carballo-Carbajal I, Jiménez-Delgado S,
Caig C, Mora S, et al. Disease-specific phenotypes in dopamine neurons
from human iPS-based models of genetic and sporadic Parkinson’s disease.
EMBO Mol Med. 2012;4:380–95.
67. Reinhardt P, Schmid B, Burbulla LF, Schöndorf DC, Wagner L, Glatza M, et al.
Genetic correction of a LRRK2 mutation in human iPSCs links parkinsonian
neurodegeneration to ERK-dependent changes in gene expression. Cell
Stem Cell. 2013;12:354–67.
Roosen and Cookson Molecular Neurodegeneration  (2016) 11:73 Page 9 of 10
68. Bravo-San Pedro JM, Niso-Santano M, Gómez-Sánchez R, Pizarro-Estrella E,
Aiastui-Pujana A, Gorostidi A, et al. The LRRK2 G2019S mutant exacerbates
basal autophagy through activation of the MEK/ERK pathway. Cell Mol Life
Sci. 2013;70:121–36.
69. Ramonet D, Daher JPL, Lin BM, Stafa K, Kim J, Banerjee R, et al. Dopaminergic
neuronal loss, reduced neurite complexity and autophagic abnormalities in
transgenic mice expressing G2019S mutant LRRK2. PLoS One. 2011;6:e18568.
70. Paxinou E, Chen Q, Weisse M, Giasson BI, Norris EH, Rueter SM, et al.
Induction of alpha-synuclein aggregation by intracellular nitrative insult.
J Neurosci Off J Soc Neurosci. 2001;21:8053–61.
71. Heo HY, Kim K-S, Seol W. Coordinate regulation of neurite outgrowth by
LRRK2 and its interactor, Rab5. Exp Neurobiol. 2010;19:97.
72. Waschbüsch D, Michels H, Strassheim S, Ossendorf E, Kessler D, Gloeckner CJ,
et al. LRRK2 transport is regulated by its novel interacting partner Rab32. PLoS
One. 2014;9:e111632.
73. Beilina A, Rudenko IN, Kaganovich A, Civiero L, Chau H, Kalia SK, et al.
Unbiased screen for interactors of leucine-rich repeat kinase 2 supports a
common pathway for sporadic and familial Parkinson disease. Proc Natl
Acad Sci U S A. 2014;111:2626–31.
74. Fukuzono T, Pastuhov SI, Fukushima O, Li C, Hattori A, Iemura S-I, et al.
Chaperone complex BAG2-HSC70 regulates localization of Caenorhabditis
elegans leucine-rich repeat kinase LRK-1 to the Golgi. Genes Cells Devoted
Mol Cell Mech. 2016;21:311–24.
75. Steger M, Tonelli F, Ito G, Davies P, Trost M, Vetter M, et al. Phosphoproteomics
reveals that Parkinson’s disease kinase LRRK2 regulates a subset of Rab GTPases.
eLife. eLife Sciences Publications, Ltd; 2016;5. doi:10.7554/eLife.12813.
76. Manzoni C, Denny P, Lovering RC, Lewis PA. Computational analysis of the
LRRK2 interactome. PeerJ. 2015;3:e778.
77. Shin N, Jeong H, Kwon J, Heo HY, Kwon JJ, Yun HJ, et al. LRRK2 regulates
synaptic vesicle endocytosis. Exp Cell Res. 2008;314:2055–65.
78. Kuwahara T, Inoue K, D’Agati VD, Fujimoto T, Eguchi T, Saha S, et al. LRRK2
and RAB7L1 coordinately regulate axonal morphology and lysosome
integrity in diverse cellular contexts. Sci Rep (Nature Publishing Group).
2016;6:29945.
79. Dodson MW, Leung LK, Lone M, Lizzio MA, Guo M. Novel ethyl
methanesulfonate (EMS)-induced null alleles of the Drosophila homolog
of LRRK2 reveal a crucial role in endolysosomal functions and autophagy
in vivo. Dis Model Mech. 2014;7:1351–63.
80. Marín I. Ancient origin of the Parkinson disease gene LRRK2. J Mol Evol.
2008;67:41–50.
81. Gómez-Suaga P, Rivero-Ríos P, Fdez E, Blanca Ramírez M, Ferrer I, Aiastui A,
et al. LRRK2 delays degradative receptor trafficking by impeding late
endosomal budding through decreasing Rab7 activity. Hum Mol Genet.
2014;23:6779–96.
82. Cho HJ, Yu J, Xie C, Rudrabhatla P, Chen X, Wu J, et al. Leucine-rich repeat
kinase 2 regulates Sec16A at ER exit sites to allow ER-Golgi export. EMBO J.
2014;33:2314–31.
83. Matta S, Van Kolen K, da Cunha R, van den Bogaart G, Mandemakers W,
Miskiewicz K, et al. LRRK2 controls an EndoA phosphorylation cycle in
synaptic endocytosis. Neuron. 2012;75:1008–21.
84. Arranz AM, Delbroek L, Van Kolen K, Guimarães MR, Mandemakers W,
Daneels G, et al. LRRK2 functions in synaptic vesicle endocytosis through
a kinase-dependent mechanism. J. Cell Sci. 2014;128:541–52.
85. Soukup S-F, Kuenen S, Vanhauwaert R, Manetsberger J, Hernández-Díaz S,
Swerts J, et al. A LRRK2-Dependent EndophilinA Phosphoswitch Is Critical
for Macroautophagy at Presynaptic Terminals. Neuron. 2016;92:6982–7.
86. Okatsu K, Koyano F, Kimura M, Kosako H, Saeki Y, Tanaka K, et al. Phosphorylated
ubiquitin chain is the genuine Parkin receptor. J Cell Biol. 2015;209:111–28.
87. Cookson MR. Parkinsonism Due to Mutations in PINK1, Parkin, and DJ-1 and
Oxidative Stress and Mitochondrial Pathways. Cold Spring Harb. Perspect.
Med. 2012;2:1–11.
88. Kane LA, Lazarou M, Fogel AI, Li Y, Yamano K, Sarraf SA, et al. PINK1
phosphorylates ubiquitin to activate parkin E3 ubiquitin ligase activity.
J Cell Biol. 2014;205:143–53.
89. Koyano F, Okatsu K, Kosako H, Tamura Y, Go E, Kimura M, et al. Ubiquitin is
phosphorylated by PINK1 to activate parkin. Nature (Nature Publishing Group).
2014;510:162–6.
90. Thomas KJ, McCoy MK, Blackinton J, Beilina A, van der Brug M, Sandebring A,
et al. DJ-1 acts in parallel to the PINK1/parkin pathway to control
mitochondrial function and autophagy. Hum Mol Genet. 2011;20:40–50.
91. Wang X, Petrie TG, Liu Y, Liu J, Fujioka H, Zhu X. Parkinson’s disease-
associated DJ-1 mutations impair mitochondrial dynamics and cause
mitochondrial dysfunction. J Neurochem. 2012;121:830–9.
92. Burchell VS, Nelson DE, Sanchez-Martinez A, Delgado-Camprubi M, Ivatt RM,
Pogson JH, et al. The Parkinson’s disease-linked proteins Fbxo7 and Parkin
interact to mediate mitophagy. Nat Neurosci. 2013;16:1257–65.
93. Xilouri M, Vogiatzi T, Vekrellis K, Park D, Stefanis L. Abberant α-synuclein
confers toxicity to neurons in part through inhibition of chaperone-
mediated autophagy. PLoS One. 2009;4:16–20.
94. Zimprich A, Benet-Pagès A, Struhal W, Graf E, Eck SH, Offman MN, et al. A
mutation in VPS35, encoding a subunit of the retromer complex, causes
late-onset parkinson disease. Am J Hum Genet. 2011;89:168–75.
95. Vilariño-Güell C, Wider C, Ross OA, Dachsel JC, Kachergus JM, Lincoln SJ, et
al. VPS35 mutations in parkinson disease. Am J Hum Genet. 2011;89:162–7.
96. Ramirez A, Heimbach A, Gründemann J, Stiller B, Hampshire D, Cid LP, et al.
Hereditary parkinsonism with dementia is caused by mutations in ATP13A2,
encoding a lysosomal type 5 P-type ATPase. Genetics. 2006;38:1184–91.
97. Elsayed LEO, Drouet V, Usenko T, Mohammed IN, Hamed AAA, Elseed MA,
et al. A novel nonsense mutation in DNAJC 6 expands the phenotype
of autosomal-recessive juvenile-onset Parkinson’s disease. Ann Neurol.
2016;79:335–7.
98. Olgiati S, Quadri M, Fang M, Rood JPMA, Saute JA, Chien HF, et al. DNAJC6
mutations associated with early-onset Parkinson’s disease. Ann Neurol.
2016;79:244–56.
99. Krebs CE, Karkheiran S, Powell JC, Cao M, Makarov V, Darvish H, et al. The sac1
domain of SYNJ1 identified mutated in a family with early-onset progressive
parkinsonism with generalized seizures. Hum Mutat. 2013;34:1200–7.
100. Sidransky E, Nalls MA, Ph D, Aasly JO, Annesi G, Barbosa ER, et al. Multi-center
analysis of glucocerebrosidase mutations in Parkinson disease. N Engl J Med.
2010;361:1651–61.
101. Deng H-X, Shi Y, Yang Y, Ahmeti KB, Miller N, Huang C, et al. Identification
of TMEM230 mutations in familial Parkinson’s disease. Nat Genet. Nature
Publishing Group; 2016;advance on:733–9.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Roosen and Cookson Molecular Neurodegeneration  (2016) 11:73 Page 10 of 10
